Newbury Pharmaceuticals AB (publ) (STO:NEWBRY)
Sweden · Delayed Price · Currency is SEK 1.135
-0.130 (-10.28%)
Jan 21, 2026, 2:48 PM CET
Newbury Pharmaceuticals AB Company Description
Newbury Pharmaceuticals AB (publ) operates as hybrid pharmaceutical company in Sweden and the Scandinavian market.
The company offers oncology, rare diseases, neurology, and other treatment products. Newbury Pharmaceuticals AB (publ) was incorporated in 2020 and is based in Lund, Sweden.
Newbury Pharmaceuticals AB (publ)
| Country | Sweden |
| Founded | 2020 |
| Industry | Drug Manufacturers - Specialty & Generic |
| Sector | Healthcare |
| Employees | 6 |
| CEO | Karl Alexius Tiger Karlsson |
Contact Details
Address: Medicon Village Lund, 223 81 Sweden | |
| Phone | 46 46 12 11 20 |
| Website | newburypharma.com |
Stock Details
| Ticker Symbol | NEWBRY |
| Exchange | Nasdaq Stockholm |
| Fiscal Year | September - August |
| Reporting Currency | SEK |
| ISIN Number | SE0015244884 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Karl Alexius Tiger Karlsson | Founder, Chief Executive Officer and Director |
| Christoffer Tell | Chief Financial Officer |
| Fredrik Hellqvist | General Manager for Nordics |